Allogene Therapeutics, Inc.
(NASDAQ : ALLO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -0.05%66.981.0%$1018.48m
BIIBBiogen, Inc. 1.05%340.631.5%$705.14m
AMGNAmgen, Inc. 0.59%223.001.3%$580.04m
ILMNIllumina, Inc. 1.01%302.963.5%$435.55m
REGNRegeneron Pharmaceuticals, Inc. -0.05%397.452.6%$375.81m
VRTXVertex Pharmaceuticals, Inc. 0.49%247.141.9%$349.62m
ALXNAlexion Pharmaceuticals, Inc. 0.51%102.682.0%$210.72m
EXASEXACT Sciences Corp. 3.31%102.8924.0%$171.83m
AAgilent Technologies, Inc. -1.17%83.801.6%$151.21m
SGENSeattle Genetics, Inc. 0.07%120.056.1%$118.62m
MRNAModerna, Inc. 0.32%18.970.0%$109.39m
INCYIncyte Corp. 2.79%81.522.5%$104.65m
XLRNAcceleron Pharma, Inc. -0.20%94.126.1%$97.07m
SRPTSarepta Therapeutics, Inc. -0.11%122.6414.6%$93.66m
ALNYAlnylam Pharmaceuticals, Inc. 0.22%128.978.7%$93.56m

Company Profile

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam on November 2017 and is headquartered in South San Francisco, CA.